Plasma Cell Myeloma Clinical Trial
Official title:
Lenalidomide Maintenance in Plasma Cell Myeloma
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Completed |
NCT02513186 -
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Completed |
NCT02880228 -
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT04782687 -
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT02514668 -
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT03417284 -
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05142371 -
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors
|
N/A | |
| Terminated |
NCT03272633 -
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
|
Early Phase 1 | |
| Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
| Active, not recruiting |
NCT03275285 -
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
|
Phase 3 | |
| Completed |
NCT04100044 -
Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma
|
N/A | |
| Active, not recruiting |
NCT00075478 -
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 3 | |
| Recruiting |
NCT05561387 -
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
|
Phase 3 | |
| Completed |
NCT03317899 -
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT05511428 -
Home Based Daratumumab Administration for Patients With Multiple Myeloma
|
Early Phase 1 | |
| Completed |
NCT01919619 -
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
|
Phase 2 | |
| Terminated |
NCT02353572 -
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04537871 -
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
|
||
| Active, not recruiting |
NCT00719888 -
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
|
Phase 2 |